REMARKS

Applicants elect Group I, that is claims 1, and 43 to 65, wherein the enhancer is caprylic acid or an either, salt, or anionic derivative thereof. Applicants submit that once these claims with this particular enhancer are deemed patentable, claims that utilize the other enhancers (nonanoic acid and capric acid) should be examined. This was confirmed by the Examiner in a teleconference with the undersigned, dated September 26, 2006.

Applicants also elect an oligonucleotide and further elect an antisense oligonucleotide including a gene encoding for an RNA that functions in an antisense capacity. Applicants submit that once these claims with this particular enhancer are deemed patentable, claims that utilize other types of nucleic acids (e.g., plasmids and ribozymes) as well as other types of oligonucleotides (e.g., triplex forming oligonucleotides and oligonucleotides that act as adjuvants) should be examined. This was confirmed by the Examiner in a teleconference with the undersigned, dated September 26, 2006.

Applicants also hereby elect the species of oligonucleotide having a modified backbone. This species is readable on claims 1, 50, and 51.

The Commissioner is authorized hereby to charge any fees or credit any overpayment associated with this Reply to Deposit Account Number 19-5425.

Respectfully submitted,

Jonathan M. Dermott, Ph.D

Reg. No. 48,608

Synnestvedt & Lechner LLP 2600 Aramark Tower 1101 Market Street Philadelphia, PA 19107-2950 Telephone - (215) 923-4466 Facsimile - (215) 923-2189

S:\M\MERRION\Patents\P24376-A USA\PTO\P24,376-A USA response to restriction requirement2.doc